Mabwell (shanghai) Bioscience Co., Ltd.
Clinical trials sponsored by Mabwell (shanghai) Bioscience Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New shot may help heal tough scars Results expected Dec 2026 (estimated)
- New hope for tough breast cancer: experimental drug BFv targets tumors after other treatments fail Results expected May 2027 (estimated)
- New hope for stubborn gut cancers? early trial launches Results expected Jul 2027 (estimated)
- New hope for advanced tumors? first human trial of 7MW4911 begins Results expected Jul 2027 (estimated)
-
Can a biosimilar match prolia in strengthening bones?
Disease control CompletedThis trial tests whether an experimental biosimilar called 9MW0311 works as well as the established drug Prolia (both containing denosumab) in postmenopausal women with osteoporosis who are at high risk for fractures. Participants receive either 9MW0311 or Prolia as an injection …
Phase 3 • Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug 9MW1911 tested for safety in first human trial
Symptom relief CompletedThis Phase 1 trial tested the safety and tolerability of a new drug called 9MW1911 in 48 healthy adults. The drug is being developed for asthma, COPD, and atopic dermatitis. Participants received either the drug or a placebo by IV infusion, and researchers monitored side effects …
Phase 1 • Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
First human tests begin for potential lung and tumor drug
Knowledge-focused CompletedThis study tested a new drug called 9MW3811 for the first time in humans. The main goal was to check if it is safe and how well it is tolerated in 32 healthy adults aged 18 to 55. Researchers gave a single dose and monitored for side effects, measuring how the drug moves through …
Phase 1 • Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC